Sino Biopharmaceutical Limited (SBMFF)
OTCMKTS
· Delayed Price · Currency is USD
0.4935
+0.0257 (5.49%)
At close: Apr 22, 2025
Sino Biopharmaceutical Revenue
In the year 2024, Sino Biopharmaceutical had annual revenue of 28.87B CNY with 10.18% growth. Sino Biopharmaceutical had revenue of 12.99B in the half year ending December 31, 2024.
Revenue
28.87B CNY
Revenue Growth
+14.93%
P/S Ratio
2.26
Revenue / Employee
1.18M CNY
Employees
24,379
Market Cap
8.93B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.87B | 2.67B | 10.18% |
| Dec 31, 2023 | 26.20B | 173.25M | 0.67% |
| Dec 31, 2022 | 26.03B | -835.19M | -3.11% |
| Dec 31, 2021 | 26.86B | 3.21B | 13.59% |
| Dec 31, 2020 | 23.65B | -586.81M | -2.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Sino Biopharmaceutical News
- 8 months ago - Sino Biopharmaceutical Limited goes ex-dividend tomorrow - Seeking Alpha
- 1 year ago - Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln - Reuters
- 4 years ago - Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea - Forbes
- 4 years ago - Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day - Seeking Alpha